Madrigal Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Madrigal Pharmaceuticals

01/05/2025 14:31

Madrigal Pharmaceuticals Inc MDGL.OQ reported a quarterly adjusted loss of $3.32​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-7.38.  The mean expectation of thirteen analysts for the quarter was for a loss of $3.69 per share. Wall Street expected results to range from $-4.91 to $-2.71 per share.

Revenue was $137.25 million​; analysts expected $113.76 million.

Madrigal Pharmaceuticals Inc's reported EPS for the quarter was a loss of $3.32​.

The company reported a quarterly loss of $73.24 million.

Madrigal Pharmaceuticals Inc shares had risen by 0.8% this quarter and gained 8.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $405.00

This summary was machine generated from LSEG data May 1 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-3.69
-3.32
Beat
Dec. 31 2024
-4.24
-2.71
Beat
Sep. 30 2024
-6.91
-4.92
Beat
Jun. 30 2024
-7.53
-7.10
Beat